Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

New drug for irregular heartbeat


Patients with an irregular heartbeat have been given new hope after the trial of a new drug showed it can significantly reduce the chance of blood clots and stroke.

According to results of the trial, which involved 14,000 patients, rivaroxaban can cut the risk of stroke and blood clots by up to a fifth when compared with the standard drug used, called warfarin.

A normal resting heart rate should be between 60 and 100 beats a minute, but an irregular heartbeat, also known as atrial fibrilation (AF), occurs when the heart beats out of synch or is abnormally fast.

In some cases the heart rate can be as high as 140 beats a minute.

AF can come in three major forms, with episodes lasting from between 48 hours to more than a year.

The condition is the most common heart rhythm disturbance and affects around 800,000 people in the UK - one in 100 people. It is more common among the elderly, with about one in 10 of those over 75 suffering from AF.

Both rivaroxaban and warfarin work by thinning the blood to reduce the risk of clots. Rivaroxaban is already recommended on the NHS to prevent blood clots in people undergoing hip and knee replacement surgery.

In the new study, researchers from the University of Edinburgh and Duke University in North Carolina, in the US, found rivaroxaban cut the risk of blood clots and strokes by an extra fifth compared with warfarin.

Patients treated with warfarin are half as likely to have a stroke compared with those taking no treatment or aspirin, but the dose needs to be closely monitored by medical staff, sometimes once a week.

Too high a dose can lead to internal bleeding, which can prove fatal, and too low a dose increases the risk of stroke.

The researchers behind the study said rivaroxaban does not need to be monitored as closely and is not affected by certain foods or alcohol.

They found rivaroxaban did not increase the risk of internal bleeding compared with warfarin, suggesting that it is a suitable alternative.

Keith Fox, British Heart Foundation professor of cardiology at the University of Edinburgh, presented the research - carried out in 45 countries - at the American Heart Association conference in Chicago.


Readers' comments (2)

  • On Monday I met a friend for lunch. During our journey she told me that following a minor hospital procedure a few months ago she was told she had an irregular heart beat. Then a fortnight ago during a routine check with her practice nurse she was told she had an irregular pulse and was asked if she 'felt ok'. 'yes' was her reply. 'well thats ok then' or words to that effect was what she was told.
    She asked me if I thought she should see her GP, she didnt want to fuss because two health care professionals hadnt thought it sigificant.
    I advised her to see her GP as soon as possible. During lunch just 1 hour later she had a CVA. Now this very proper and eloquent lady who was very independent, active and always proactive in a healthy lifestyle, is unable to speak, unable to swallow (is tube fed) and has a dense Right sided weakness.
    I feel distraught for her and for her family that this 'accident' could have been avoided. My plea is to all health care professionals not to ignore an irregular pulse

    Unsuitable or offensive? Report this comment

  • A very alarming story which could affect anybody but a helpful reminder to be more attentive. It is surprising it wasn't investigated earlier.

    Unsuitable or offensive? Report this comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs